Group develops method of killing cancer cells with antibodies and light

November 7, 2011 by Bob Yirka report

(Medical Xpress) -- Traditionally, there are three major ways to combat cancer in people: surgical removal, radiation therapy and chemotherapy. And while all three have been proven to be effective in treating some types of cancer, all three also have unpleasant side effects. It’s for this reason that researchers continue to try to find other ways to kill cancer cells. Now, in a paper published in Nature Medicine, a team from the National Cancer Institute in the United States, says that it has developed a type of photoimmunotherapy that combines a light-sensitive dye that has a special chemical in it and antibodies to target and kill cancer cells when light is shined on them.

Photoimmunotherapy has been tried before, but not in this way, in previous research such antibodies were not nearly so target specific, meaning they tended to kill other cells as well. In this latest research, the team was able to use tumor specific antibodies that would attach themselves to the , but would remain dormant. It was only when the same cancer cells were also exposed to a chemical called IR700 and then exposed to light that the antibodies went to work killing the cancer cells.

In their lab studies, the team inserted a type of skin cancer into the skin on the back of a mouse; when given the drug and then exposed to light, the research team found that the size of the tumor in the mouse was significantly reduced compared to control mice. They also found that other cells around the tumor were unaffected and that there didn’t appear to be any toxic reactions to the treatment.

It’s not yet known if the procedure would work in humans, but further research is likely to be done in a lot of areas, likely including other types of animals before tests can be conducted with human volunteers. Also, research is continuing to see if it might be possible to use to deliver other sorts of cancer killing agents, such as radiation.

If such types of photoimmunotherapy prove workable, millions of people the world over might be spared the pain of surgery and/or the harmful side effects of radiation and .

Explore further: Pancreas betrayed by 'double agent'

More information: Cancer cell–selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules, Nature Medicine (2011) doi:10.1038/nm.2554

Three major modes of cancer therapy (surgery, radiation and chemotherapy) are the mainstay of modern oncologic therapy. To minimize the side effects of these therapies, molecular-targeted cancer therapies, including armed antibody therapy, have been developed with limited success. In this study, we have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was induced immediately after irradiating mAb-IR700–bound target cells with NIR light. We observed in vivo tumor shrinkage after irradiation with NIR light in target cells expressing the epidermal growth factor receptor. The mAb-IR700 conjugates were most effective when bound to the cell membrane and produced no phototoxicity when not bound, suggesting a different mechanism for PIT as compared to conventional photodynamic therapies. Target-selective PIT enables treatment of cancer based on mAb binding to the cell membrane.

Related Stories

Pancreas betrayed by 'double agent'

May 30, 2011
(Medical Xpress) -- Stellate cells, a type of cell in the pancreas which normally helps the body respond to damage or disease of the pancreas, can act as a double agent when it comes to cancer.

Stem cells, potential source of cancer-fighting T cells

September 20, 2011
Adult stem cells from mice converted to antigen-specific T cells -- the immune cells that fight cancer tumor cells -- show promise in cancer immunotherapy and may lead to a simpler, more efficient way to use the body's immune ...

Recommended for you

Study provides insight into link between two rare tumor syndromes

August 22, 2017
UCLA researchers have discovered that timing is everything when it comes to preventing a specific gene mutation in mice from developing rare and fast-growing cancerous tumors, which also affects young children. This mutation ...

Retaining one normal BRCA gene in breast, ovarian cancers influences patient survival

August 22, 2017
Determining which cancer patients are likely to be resistant to initial treatment is a major research effort of oncologists and laboratory scientists. Now, ascertaining who might fall into that category may become a little ...

Study identifies miR122 target sites in liver cancer and links a gene to patient survival

August 22, 2017
A new study of a molecule that regulates liver-cell metabolism and suppresses liver-cancer development shows that the molecule interacts with thousands of genes in liver cells, and that when levels of the molecule go down, ...

Zebrafish larvae could be used as 'avatars' to optimize personalized treatment of cancer

August 21, 2017
Portuguese scientists have for the first time shown that the larvae of a tiny fish could one day become the preferred model for predicting, in advance, the response of human malignant tumors to the various therapeutic drugs ...

Scientists discover vitamin C regulates stem cell function, curbs leukemia development

August 21, 2017
Not much is known about stem cell metabolism, but a new study from the Children's Medical Center Research Institute at UT Southwestern (CRI) has found that stem cells take up unusually high levels of vitamin C, which then ...

Searching for the 'signature' causes of BRCAness in breast cancer

August 21, 2017
Breast cancer cells with defects in the DNA damage repair-genes BRCA1 and BRCA2 have a mutational signature (a pattern of base swaps—e.g., Ts for Gs, Cs for As—throughout a genome) known in cancer genomics as "Signature ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Nov 07, 2011
I love this story. Wonder if just visible light is the only activator however. How nice if terahertz radiation as opposed to visible light radiation could also be used. Reason being is that terahertz radiation could penetrate deeper than visible light with probably no damage to tissue...hey the Transport Security boys and girls use it to gawk at all the women and men airline passenger's 'soft parts' disrespectfully so this has the USDA mark of 'approval'. Then all kidding aside, two terahertz laser beams could be used to intersect in three dimensional space inside the patient's body at the precise intended treatment location; uniting with the antibodies there to destroy the cancers without surgery.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.